Publikation: Zeitschriftenartikel

Liver SBRT with active motion-compensation results in excellent local control for liver oligometastases

Grunddaten
Abstract
Autoren
Einrichtung

Grunddaten

Titel	Liver SBRT with active motion-compensation results in excellent local control for liver oligometastases
Untertitel	an outcome analysis of a pooled multi-platform patient cohort
Erscheinungsjahr	2021
Seiten (von – bis)	230 – 236
Band	158
Jahr	2021
Publikationsform	Elektronische Ressource
Publikationsart	Zeitschriftenartikel
Sprache	Englisch
DOI	10.1016/j.radonc.2021.02.036
Letzte Änderung	25.02.2022 06:02:30
Bearbeitungsstatus	durch UB Rostock abschließend validiert
Dauerhafte URL	http://purl.uni-rostock.de/fodb/pub/67633
Links zu Katalogen

Abstract

Background - Local treatment of metastases in combination with systemic therapy can prolong survival of oligo-metastasized patients. To fully exploit this potential, safe and effective treatments are needed to ensure long-term metastases control. Stereotactic body radiotherapy (SBRT) is one means, however, for moving liver tumors correct delivery of high doses is challenging. After validating equal in-vivo treatment accuracy, we analyzed a pooled multi-platform liver-SBRT-database for clinical outcome. - Methods - Local control (LC), progression-free interval (PFI), overall survival (OS), predictive factors and toxicity was evaluated in 135 patients with 227 metastases treated by gantry-based SBRT (deep-inspiratory breath-hold-gating; n = 71) and robotic-based SBRT (fiducial-tracking, n = 156) with mean gross tumor volume biological effective dose (GTV-BED/=10Gy) of 146.6 Gy10. - Results - One-, and five-year LC was 90% and 68.7%, respectively. On multivariate analysis, LC was significantly predicted by colorectal histology (p = 0.006). Median OS was 20 months with one- and two-year OS of 67% and 37%. On multivariate analysis, ECOG-status (p = 0.003), simultaneous chemotherapy (p = 0.003), time from metastasis detection to SBRT-treatment (2months; p = 0.021) and LC of the treated metastases (12 months, p < 0.009) were significant predictors for OS. One- and two-year PFI were 30.5% and 14%. Acute toxicity was mild and rare (14.4% grade I, 2.3% grade II, 0.6% grade III). Chronic °III/IV toxicities occurred in 1.1%. - Conclusions - Patient selection, time to treatment and sufficient doses are essential to achieve optimal outcome for SBRT with active motion compensation. Local control appears favorable compared to historical control. Long-term LC of the treated lesions was associated with longer overall survival.

Autoren

Stera, Susanne

Miebach, Georgia

Bürgy, Daniel

Dreher, Constantin

Lohr, Frank

Wurster, Stefan

Rödel, Claus

Marcella, Szücs

Krug, David

Frank A., Giordano

Ehmann, Michael

Fleckenstein, Jens

Blanck, Oliver

Boda-Heggemann, Judit

Einrichtung

UMR/Zentrum für Radiologie